 TRACON Pharmaceuticals Inc announced that it has ended its third-quarter 2022 with cash and equivalents of 17.0 million as of September 30, 2022, which the company says is expected to fund its operations into mid-2023. The clinical stage biopharmaceutical company also noted that its net loss for the quarter narrowed to 6.4 million from 7.0 million a year earlier, as it reduced its general and administrative expenses for the period to 2.3 million, compared to 4.2 million in 3Q 2021. 